medigraphic.com
ISSN 2500-7106 (Digital)
ISSN 0123-2576 (Impreso)
Medicina & Laboratorio

2021, Número 2

<< Anterior Siguiente >>

Medicina & Laboratorio 2021; 25 (2)


Microangiopatías trombóticas primarias: una revisión narrativa

Henao-Piedrahita N

Idioma: Español
Referencias bibliográficas: 63
Paginas: 485-499
Archivo PDF: 117.01 Kb.


RESUMEN

La microangiopatía trombótica (MAT) es un síndrome donde hay formación de microtrombos en la circulación que llevan a anemia hemolítica microangiopática (AHMA) y trombocitopenia con falla multiorgánica, debido a la isquemia de los tejidos. Las MAT pueden ser primarias sin causa subyacente asociada, como la púrpura trombocitopénica trombótica debida a deficiencia de la enzima ADAMTS13, el síndrome hemolítico urémico debido a la toxina Shiga de Escherichia coli enterohemorrágica, y la MAT producida por alteraciones en la regulación del complemento. Adicionalmente, pueden ser secundarias a enfermedades malignas, infecciosas, metabólicas, autoinmunes o inducidas por el embarazo. Estas patologías requieren diagnóstico y tratamiento oportunos debido a que tienen alta morbimortalidad y se asocian a complicaciones que incluyen enfermedad renal, alteraciones neurológicas como convulsiones, accidente cerebrovascular, coma y muerte. El tratamiento es multidisciplinario y se enfoca en el soporte hemodinámico, transfusional y en el manejo de la etiología cuando esta es identificada. La siguiente revisión pretende explicar de forma clara y precisa los aspectos generales de las MAT primarias.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Moschcowitz E. An acute febrile pleiochromicanemia with hyaline thrombosis of the terminalarterioles and capillaries; an undescribed disease.Am J Med 1952;13:567-569. https://doi.org/10.1016/0002-9343(52)90022-3.

  2. Contreras E, De la Rubia J, del Río-GarmaJ, Díaz-Ricart M, García-Gala JM, Lozano M.Guía diagnóstica y terapéutica de las microangiopatíastrombóticas del Grupo Español deAféresis. Med Clin 2015;144:e1-e13. https://doi.org/10.1016/j.medcli.2014.09.013.

  3. Arnold DM, Patriquin CJ, Nazy I. Thromboticmicroangiopathies: a general approach to diagnosisand management. CMAJ 2017;189:E153-E159. https://doi.org/10.1503/cmaj.160142.

  4. Radhakrishnan J. Anticomplement therapies in“secondary thrombotic microangiopathies”: readyfor prime time? Kidney Int 2019;96:833-835.https://doi.org/10.1016/j.kint.2019.08.005.

  5. George JN, Nester CM. Syndromes ofthrombotic microangiopathy. N Engl J Med2014;371:654-666. https://doi.org/10.1056/NEJMra1312353.

  6. Moake JL. Thrombotic microangiopathies.N Engl J Med 2002;347:589-600. https://doi.org/10.1056/NEJMra020528.

  7. Romero S, Sempere A, Gómez-Seguí I, RománE, Moret A, Jannone R, et al. Guía prácticade tratamiento urgente de la microangiopatíatrombótica. Med Clin 2018;151:123.e121-123.e129. https://doi.org/https://doi.org/10.1016/j.medcli.2018.01.013.

  8. George JN, Nester CM. Approach to the patientwith suspected TTP, HUS, or other thromboticmicroangiopathy (TMA). Massachusetts,Estados Unidos: Wolters Kluwer Health; 2019.Acceso 20 de agosto de 2020. Disponible enhttps://www.uptodate.com/contents/approachto-the-patient-with-suspected-ttp-hus-or-otherthrombotic-microangiopathy-tma#H16673902.

  9. Nokes T, George JN, Vesely SK, AwabA. Pulmonary involvement in patients withthrombotic thrombocytopenic purpura. EurJ Haematol 2014;92:156-163. https://doi.org/10.1111/ejh.12222.

  10. Blasco-Pelicano M, Guillé E, Quintana L, Garcia-Herrera A, Piñeiro G, Poch E, et al. Thromboticmicroangiopathies assessment: mind thecomplement. Clin Kidney J 2020;2020:sfaa195.https://doi.org/10.1093/ckj/sfaa195.

  11. Eskazan AE, Salihoglu A. Treatment and outcomeof primary and secondary thrombotic microangiopathies.Am J Nephrol 2015;41:427-428. https://doi.org/10.1159/000437002.

  12. Kremer Hovinga JA, Coppo P, LämmleB, Moake JL, Miyata T, Vanhoorelbeke K.Thrombotic thrombocytopenic purpura. NatRev Dis Primers 2017;3:17020. https://doi.org/10.1038/nrdp.2017.20.

  13. Joly BS, Coppo P, Veyradier A. An updateon pathogenesis and diagnosis of thromboticthrombocytopenic purpura. Expert Rev Hematol2019;12:383-395. https://doi.org/10.1080/17474086.2019.1611423.

  14. Shatzel JJ, Taylor JA. Syndromes of thromboticmicroangiopathy. Med Clin North Am2017;101:395-415. https://doi.org/10.1016/j.mcna.2016.09.010.

  15. George JN. Thrombotic microangiopathy(TMA). Platelets on the Web. Oklahoma, USA:University of Oklahoma Health Sciences Center;2007. Acceso 5 de agosto de 2020. Disponibleen https://www.ouhsc.edu/platelets/TMA.htm.

  16. Reese JA, Muthurajah DS, Kremer HovingaJA, Vesely SK, Terrell DR, George JN. Children and adults with thrombotic thrombocytopenicpurpura associated with severe, acquiredAdamts13 deficiency: comparison of incidence,demographic and clinical features. PediatrBlood Cancer 2013;60:1676-1682. https://doi.org/10.1002/pbc.24612.

  17. Terrell DR, Williams LA, Vesely SK, Lämmle B,Hovinga JA, George JN. The incidence of thromboticthrombocytopenic purpura-hemolytic uremicsyndrome: all patients, idiopathic patients,and patients with severe ADAMTS-13 deficiency.J Thromb Haemost 2005;3:1432-1436. https://doi.org/10.1111/j.1538-7836.2005.01436.x.

  18. Terrell DR, Vesely SK, Kremer Hovinga JA,Lämmle B, George JN. Different disparities ofgender and race among the thrombotic thrombocytopenicpurpura and hemolytic-uremicsyndromes. Am J Hematol 2010;85:844-847.https://doi.org/10.1002/ajh.21833.

  19. Moake JL, Rudy CK, Troll JH, Weinstein MJ,Colannino NM, Azocar J, et al. Unusuallylarge plasma factor VIII:von Willebrand factormultimers in chronic relapsing thromboticthrombocytopenic purpura. N Engl J Med1982;307:1432-1435. https://doi.org/10.1056/nejm198212023072306.

  20. Asada Y, Sumiyoshi A, Hayashi T, Suzumiya J,Kaketani K. Immunohistochemistry of vascularlesion in thrombotic thrombocytopenic purpura,with special reference to factor VIII relatedantigen. Thromb Res 1985;38:469-479. https://doi.org/10.1016/0049-3848(85)90180-x.

  21. Vacca VM, Jr. Acquired autoimmune thromboticthrombocytopenic purpura. Nursing2019;49:22-29. https://doi.org/10.1097/01.NURSE.0000549721.69197.4d.

  22. Moake JL, Turner NA, Stathopoulos NA, NolascoLH, Hellums JD. Involvement of largeplasma von Willebrand factor (vWF) multimersand unusually large vWF forms derived fromendothelial cells in shear stress-induced plateletaggregation. J Clin Invest 1986;78:1456-1461. https://doi.org/10.1172/jci112736.

  23. Zander CB, Cao W, Zheng XL. ADAMTS13and von Willebrand factor interactions. CurrOpin Hematol 2015;22:452-459. https://doi.org/10.1097/moh.0000000000000169.

  24. Furlan M, Robles R, Galbusera M, Remuzzi G,Kyrle PA, Brenner B, et al. von Willebrand factorcleavingprotease in thrombotic thrombocytopenicpurpura and the hemolytic-uremic syndrome.N Engl J Med 1998;339:1578-1584. https://doi.org/10.1056/nejm199811263392202.

  25. Blombery P, Scully M. Management of thromboticthrombocytopenic purpura: current perspectives.J Blood Med 2014;5:15-23. https://doi.org/10.2147/jbm.S46458.

  26. Kappler S, Ronan-Bentle S, Graham A.Thrombotic microangiopathies (TTP, HUS,HELLP). Hematol Oncol Clin North Am2017;31:1081-1103. https://doi.org/10.1016/j.hoc.2017.08.010.

  27. Griffin D, Al-Nouri ZL, Muthurajah D, Ross JR,Ballard RB, Terrell DR, et al. First symptomsin patients with thrombotic thrombocytopenicpurpura: what are they and when do they occur?Transfusion 2013;53:235-237. https://doi.org/10.1111/j.1537-2995.2012.03934.x.

  28. George JN. How I treat patients with thromboticthrombocytopenic purpura: 2010. Blood2010;116:4060-4069. https://doi.org/10.1182/blood-2010-07-271445.

  29. Vesely SK, George JN, Lämmle B, StudtJD, Alberio L, El-Harake MA, et al. ADAMTS13activity in thrombotic thrombocytopenicpurpura-hemolytic uremic syndrome:relation to presenting features and clinicaloutcomes in a prospective cohort of 142patients. Blood 2003;102:60-68. https://doi.org/10.1182/blood-2003-01-0193.

  30. Brocklebank V, Wood KM, Kavanagh D.Thrombotic microangiopathy and the kidney.Clin J Am Soc Nephrol 2018;13:300-317.https://doi.org/10.2215/cjn.00620117.

  31. Bendapudi PK, Hurwitz S, Fry A, MarquesMB, Waldo SW, Li A, et al. Derivation and externalvalidation of the PLASMIC score for rapidassessment of adults with thrombotic microangiopathies:a cohort study. Lancet Haematol2017;4:e157-e164. https://doi.org/10.1016/s2352-3026(17)30026-1.

  32. George JN. Systemic malignancies as a causeof unexpected microangiopathic hemolyticanemia and thrombocytopenia. Oncology2011;25:908-914.

  33. Furlan M, Robles R, Morselli B, Sandoz P,Lämmle B. Recovery and half-life of von Willebrandfactor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenicpurpura. Thromb Haemost 1999;81:8-13.

  34. Zheng XL, Vesely SK, Cataland SR, CoppoP, Geldziler B, Iorio A, et al. ISTH guidelinesfor treatment of thrombotic thrombocytopenicpurpura. J Thromb Haemost 2020;18:2496-2502. https://doi.org/10.1111/jth.15010.

  35. Scully M, Hunt BJ, Benjamin S, Liesner R,Rose P, Peyvandi F, et al. Guidelines on thediagnosis and management of thromboticthrombocytopenic purpura and other thromboticmicroangiopathies. Br J Haematol2012;158:323-335. https://doi.org/10.1111/j.1365-2141.2012.09167.x.

  36. Schwartz J, Padmanabhan A, Aqui N, BalogunRA, Connelly-Smith L, Delaney M, et al.Guidelines on the use of therapeutic apheresisin clinical practice-evidence-based approachfrom the Writing Committee of the AmericanSociety for Apheresis: The seventh special issue.J Clin Apher 2016;31:149-162. https://doi.org/10.1002/jca.21470.

  37. Scully M, Cataland S, Coppo P, de la RubiaJ, Friedman KD, Kremer Hovinga J, et al.Consensus on the standardization of terminologyin thrombotic thrombocytopenic purpuraand related thrombotic microangiopathies. JThromb Haemost 2017;15:312-322. https://doi.org/10.1111/jth.13571.

  38. Wang HX, Han B, Zhao YY, Kou L, Guo LL,Sun TW, et al. Serum D-dimer as a potentialnew biomarker for prognosis in patients withthrombotic thrombocytopenic purpura. Medicine(Baltimore) 2020;99:e19563. https://doi.org/10.1097/md.0000000000019563.

  39. Gasser C, Gautier E, Steck A, SiebenmannRE, Oechslin R. [Hemolytic-uremic syndrome:bilateral necrosis of the renal cortex in acuteacquired hemolytic anemia]. Schweiz Med Wochenschr1955;85:905-909.

  40. Fakhouri F, Zuber J, Frémeaux-Bacchi V, LoiratC. Haemolytic uraemic syndrome. Lancet2017;390:681-696. https://doi.org/10.1016/s0140-6736(17)30062-4.

  41. Tarr PI, Gordon CA, Chandler WL. Shiga-toxinproducingEscherichia coli and haemolytic uraemicsyndrome. Lancet 2005;365:1073-1086.https://doi.org/10.1016/s0140-6736(05)71144-2.

  42. Witham PK, Yamashiro CT, Livak KJ, BattCA. A PCR-based assay for the detection of Escherichiacoli Shiga-like toxin genes in groundbeef. Appl Environ Microbiol 1996;62:1347-1353. https://doi.org/10.1128/aem.62.4.1347-1353.1996.

  43. Bell BP, Goldoft M, Griffin PM, Davis MA,Gordon DC, Tarr PI, et al. A multistate outbreakof Escherichia coli O157:H7-associatedbloody diarrhea and hemolytic uremic syndromefrom hamburgers. The Washington experience.Jama 1994;272:1349-1353.

  44. Buchholz U, Bernard H, Werber D, BöhmerMM, Remschmidt C, Wilking H, et al. Germanoutbreak of Escherichia coli O104:H4associated with sprouts. N Engl J Med2011;365:1763-1770. https://doi.org/10.1056/NEJMoa1106482.

  45. Noris M, Remuzzi G. Hemolytic uremic syndrome.J Am Soc Nephrol 2005;16:1035-1050.https://doi.org/10.1681/asn.2004100861.

  46. Cody EM, Dixon BP. Hemolytic uremic syndrome.Pediatr Clin North Am 2019;66:235-246.https://doi.org/10.1016/j.pcl.2018.09.011.

  47. Karpac CA, Li X, Terrell DR, Kremer HovingaJA, Lämmle B, Vesely SK, et al. Sporadic bloodydiarrhoea-associated thrombotic thrombocytopenicpurpura-haemolytic uraemic syndrome:an adult and paediatric comparison.Br J Haematol 2008;141:696-707. https://doi.org/10.1111/j.1365-2141.2008.07116.x.

  48. Manrique-Caballero CL, PeerapornratanaS, Formeck C, Del Rio-Pertuz G, Gomez DaniesH, Kellum JA. Typical and atypical hemolyticuremic syndrome in the critically ill.Crit Care Clin 2020;36:333-356. https://doi.org/10.1016/j.ccc.2019.11.004.

  49. Spinale JM, Ruebner RL, Copelovitch L, KaplanBS. Long-term outcomes of Shiga toxinhemolytic uremic syndrome. Pediatr Nephrol2013;28:2097-2105. https://doi.org/10.1007/s00467-012-2383-6.

  50. Garg AX, Suri RS, Barrowman N, Rehman F,Matsell D, Rosas-Arellano MP, et al. Longtermrenal prognosis of diarrhea-associatedhemolytic uremic syndrome: a systematic review,meta-analysis, and meta-regression. Jama2003;290:1360-1370. https://doi.org/10.1001/jama.290.10.1360.

  51. Taylor CM, Machin S, Wigmore SJ, GoodshipTH. Clinical practice guidelines for themanagement of atypical haemolytic uraemicsyndrome in the United Kingdom. Br J Haematol2010;148:37-47. https://doi.org/10.1111/j.1365-2141.2009.07916.x.

  52. Geerdink LM, Westra D, van Wijk JA, DorresteijnEM, Lilien MR, Davin JC, et al. Atypicalhemolytic uremic syndrome in children: complementmutations and clinical characteristics.Pediatr Nephrol 2012;27:1283-1291. https://doi.org/10.1007/s00467-012-2131-y.

  53. Hofer J, Janecke AR, Zimmerhackl LB, RiedlM, Rosales A, Giner T, et al. Complementfactor H-related protein 1 deficiency and factorH antibodies in pediatric patients withatypical hemolytic uremic syndrome. Clin JAm Soc Nephrol 2013;8:407-415. https://doi.org/10.2215/cjn.01260212.

  54. Licht C, Ardissino G, Ariceta G, Cohen D, ColeJA, Gasteyger C, et al. The global aHUS registry:methodology and initial patient characteristics.BMC Nephrol 2015;16:207. https://doi.org/10.1186/s12882-015-0195-1.

  55. Makou E, Herbert AP, Barlow PN. Functionalanatomy of complement factor H. Biochemistry2013;52:3949-3962. https://doi.org/10.1021/bi4003452.

  56. Noris M, Caprioli J, Bresin E, Mossali C, PianettiG, Gamba S, et al. Relative role of geneticcomplement abnormalities in sporadic andfamilial aHUS and their impact on clinical phenotype.Clin J Am Soc Nephrol 2010;5:1844-1859. https://doi.org/10.2215/cjn.02210310.

  57. Sellier-Leclerc AL, Fremeaux-Bacchi V, Dragon-Durey MA, Macher MA, Niaudet P, GuestG, et al. Differential impact of complementmutations on clinical characteristics in atypicalhemolytic uremic syndrome. J Am Soc Nephrol2007;18:2392-2400. https://doi.org/10.1681/asn.2006080811.

  58. Goodship TH, Cook HT, Fakhouri F, FervenzaFC, Frémeaux-Bacchi V, Kavanagh D, et al. Atypicalhemolytic uremic syndrome and C3 glomerulopathy:conclusions from a "Kidney disease:Improving global outcomes" (KDIGO) ControversiesConference. Kidney Int 2017;91:539-551.https://doi.org/10.1016/j.kint.2016.10.005.

  59. Cataland SR, Holers VM, Geyer S, YangS, Wu HM. Biomarkers of terminal complementactivation confirm the diagnosis ofaHUS and differentiate aHUS from TTP. Blood2014;123:3733-3738. https://doi.org/10.1182/blood-2013-12-547067.

  60. Noris M, Remuzzi G. Atypical hemolytic-uremicsyndrome. N Engl J Med 2009;361:1676-1687.https://doi.org/10.1056/NEJMra0902814.

  61. Masias C, Vasu S, Cataland SR. None of the above:thrombotic microangiopathy beyond TTPand HUS. Blood 2017;129:2857-2863. https://doi.org/10.1182/blood-2016-11-743104.

  62. Gordon CE, Chitalia VC, Sloan JM, SalantDJ, Coleman DL, Quillen K, et al. Thromboticmicroangiopathy: A multidisciplinary teamapproach. Am J Kidney Dis 2017;70:715-721.https://doi.org/10.1053/j.ajkd.2017.05.017.

  63. Bittencourt CE, Ha JP, Maitta RW. Re-examinationof 30-day survival and relapse rates inpatients with thrombotic thrombocytopenicpurpura-hemolytic uremic syndrome. PLoS One2015;10:e0127744. https://doi.org/10.1371/journal.pone.0127744.




2020     |     www.medigraphic.com